Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for N51517105 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Cooperatieve Gilde Healthcare IV U.A.
13D/A
Amendment 3
|
3.9% |
10/22/2025
Event 10/20/2025
|
|
| Cooperatieve Gilde Healthcare IV U.A. | 3.9% | ||
| Gilde Healthcare IV Management B.V. | 3.9% | ||
| Gilde Healthcare Holding B.V. | 3.9% | ||
| Manapouri B.V. | 3.9% | ||
| Martemanshurk B.V. | 3.9% | ||
|
Cooperatieve Gilde Healthcare IV U.A.
13D/A
Amendment 2
|
11.2% |
10/17/2025
Event 10/15/2025
|
|
| Cooperatieve Gilde Healthcare IV U.A. | 11.2% | ||
| Gilde Healthcare IV Management B.V. | 11.2% | ||
| Gilde Healthcare Holding B.V. | 11.2% | ||
| Manapouri B.V. | 11.2% | ||
| Martemanshurk B.V. | 11.2% | ||
|
Cooperatieve Gilde Healthcare IV U.A.
13D/A
Amendment 1
|
19.9% |
10/14/2025
Event 10/9/2025
|
|
| Cooperatieve Gilde Healthcare IV U.A. | 19.9% | ||
| Gilde Healthcare IV Management B.V. | 19.9% | ||
| Gilde Healthcare Holding B.V. | 19.9% | ||
| Manapouri B.V. | 19.9% | ||
| Martemanshurk B.V. | 19.9% | ||
|
Shay Capital LLC
13G
|
9.9% |
9/26/2025
Event 9/19/2025
|
|
| Shay Capital LLC | 9.9% | ||
| Shay Capital Holdings LLC | 9.9% | ||
|
Versant Venture Capital VI, L.P.
13D/A
Amendment 2
|
0% |
9/23/2025
Event 9/19/2025
|
|
| Versant Venture Capital VI, L.P. | 0% | ||
| Versant Ventures VI GP, L.P. | 0% | ||
| Versant Ventures VI GP-GP, LLC | 0% | ||
| Versant Vantage I, L.P. | 0% | ||
| Versant Vantage I GP, L.P. | 0% | ||
| Versant Vantage I GP-GP, LLC | 0% | ||
|
Versant Venture Capital VI, L.P.
13D/A
Amendment 1
|
9.0% |
9/18/2025
Event 9/16/2025
|
|
| Versant Venture Capital VI, L.P. | 9.0% | ||
| Versant Ventures VI GP, L.P. | 9.0% | ||
| Versant Ventures VI GP-GP, LLC | 9.0% | ||
| Versant Vantage I, L.P. | 2.0% | ||
| Versant Vantage I GP, L.P. | 2.0% | ||
| Versant Vantage I GP-GP, LLC | 2.0% | ||
| BML Investment Partners, L.P. 13G | 7.4% |
3/3/2025
Event 2/26/2025
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q3 | 26 | 10.3 M | $16.1 M |
| 2025 Q2 | 21 | 8.05 M | $10.6 M |
| 2025 Q1 | 22 | 8.04 M | $10.2 M |
| 2024 Q4 | 23 | 6.47 M | $6.15 M |
| 2024 Q3 | 25 | 3.61 M | $5.99 M |
| 2024 Q2 | 24 | 3.77 M | $6.79 M |
| 2024 Q1 | 28 | 3.78 M | $12.6 M |
| 2023 Q4 | 17 | 5.86 M | $9.26 M |
| 2023 Q3 | 16 | 5.72 M | $8.47 M |
| 2023 Q2 | 17 | 5.75 M | $11.7 M |
| 2023 Q1 | 20 | 6.74 M | $11.2 M |
| 2022 Q4 | 21 | 7.46 M | $26.3 M |
| 2022 Q3 | 15 | 7.68 M | $35.1 M |
| 2022 Q2 | 19 | 8.07 M | $23.5 M |
| 2022 Q1 | 20 | 8.23 M | $36.2 M |
| 2021 Q4 | 21 | 8.05 M | $44.3 M |
| 2021 Q3 | 20 | 8.22 M | $48.6 M |
| 2021 Q2 | 20 | 8.99 M | $97.9 M |
| 2021 Q1 | 25 | 9.22 M | $139 M |